Edition:
United States

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

2.92USD
11:52am EST
Change (% chg)

$-0.08 (-2.50%)
Prev Close
$3.00
Open
$2.95
Day's High
$2.95
Day's Low
$2.90
Volume
7,100
Avg. Vol
30,911
52-wk High
$6.71
52-wk Low
$2.12

LIFE.OQ

Chart for LIFE.OQ

About

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based... (more)

Overall

Beta: --
Market Cap(Mil.): $71.16
Shares Outstanding(Mil.): 23.72
Dividend: --
Yield (%): --

Financials

  LIFE.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -2.61 -- --
ROI: -59.81 -1.38 14.86
ROE: -60.83 -1.07 16.28

BRIEF-FDA grants fast track designation for aTyr's Resolaris

* Fda grants fast track designation for aTyr's Resolaris to treat limb girdle muscular dystrophy 2b and removes partial clinical hold for Resolaris

Jan 18 2017

BRIEF-Atyr Pharma enters into $20 million credit facility

* Intends to use additional capital to pay off existing indebtedness

Nov 21 2016

BRIEF-Atyr Pharma reports Q3 loss per share of $0.58

* Qtrly net loss per share attributable to common stockholders $0.58

Nov 14 2016

BRIEF-Atyr Pharma receives FDA fast track designation for Resolaris to treat FSHD

* Atyr Pharma receives FDA fast track designation for Resolaris to treat facioscapulohumeral muscular dystrophy (FSHD)

Oct 24 2016

BRIEF-Atyr Pharma Inc qtrly loss per share $0.65

* Atyr Pharma announces second quarter 2016 operating results

Aug 10 2016

Earnings vs. Estimates